Jump to main content
Jump to site search

Issue 9, 2014
Previous Article Next Article

Surface plasmon resonance-based immunoassay for human fetuin A

Author affiliations

Abstract

This article describes a highly-sensitive surface plasmon resonance (SPR)-based immunoassay (IA) for human fetuin A (HFA), a specific biomarker for atherosclerosis and hepatocellular carcinoma. The assay is based on a novel immobilization procedure that simply involves the dilution of an anti-HFA capture antibody (Ab) in 1% (v/v) 3-aminopropyltriethoxysilane (APTES), followed by its dispensing on a KOH-treated gold (Au)-coated SPR chip and incubation for 30 min. The developed SPR IA detected 0.3–20 ng mL−1 of HFA with a limit of detection and sensitivity of 0.7 ng mL−1 and 1 ng mL−1, respectively. The highly-simplified Ab immobilization procedure is also 5-fold more rapid than conventional procedures. It leads to the leach-proof binding of the capture Ab, which means that the developed SPR IA is highly cost-effective, as the Ab-bound SPR chip could be reused for many repeated HFA IAs after regeneration with 10 mM glycine–HCl, pH 2.0. The Ab-bound SPR chip, stored at 4 °C, lost only 18% of its original activity after 4 months. For the detection of HFA spiked in diluted human whole blood and plasma, the results obtained by the developed SPR IA agreed well with the commercial HFA sandwich ELISA.

Graphical abstract: Surface plasmon resonance-based immunoassay for human fetuin A

Back to tab navigation

Supplementary files

Publication details

The article was received on 20 Jan 2014, accepted on 10 Feb 2014 and first published on 12 Feb 2014


Article type: Paper
DOI: 10.1039/C4AN00149D
Citation: Analyst, 2014,139, 2237-2242
  •   Request permissions

    Surface plasmon resonance-based immunoassay for human fetuin A

    S. K. Vashist, E. M. Schneider and J. H. T. Luong, Analyst, 2014, 139, 2237
    DOI: 10.1039/C4AN00149D

Search articles by author

Spotlight

Advertisements